Business Description
Pacific Biosciences of California Inc
NAICS : 325413
SIC : 3845
ISIN : US69404D1081
Total Employee Number:
485Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Debt-to-Equity | 297.29 | |||||
Debt-to-EBITDA | -6.82 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.28 | |||||
Beneish M-Score | -2.89 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.3 | |||||
3-Year EBITDA Growth Rate | 26 | |||||
3-Year EPS without NRI Growth Rate | -9.9 | |||||
3-Year FCF Growth Rate | 31.8 | |||||
3-Year Book Growth Rate | -80.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.13 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.33 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 27.38 | |||||
14-Day RSI | 33.91 | |||||
6-1 Month Momentum % | -1.75 | |||||
12-1 Month Momentum % | 23.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.65 | |||||
Quick Ratio | 4.87 | |||||
Cash Ratio | 4.22 | |||||
Days Inventory | 190.68 | |||||
Days Sales Outstanding | 72.67 | |||||
Days Payable | 58.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.1 | |||||
Shareholder Yield % | 20.1 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.49 | |||||
Operating Margin % | -111.9 | |||||
Net Margin % | -80.35 | |||||
EBITDA Margin % | -64.43 | |||||
FCF Margin % | -75.34 | |||||
OCF Margin % | -69.64 | |||||
ROE % | -326.45 | |||||
ROA % | -15.85 | |||||
ROIC % | -38.74 | |||||
3-Year ROIIC % | 36.97 | |||||
ROC (Joel Greenblatt) % | -122.42 | |||||
ROCE % | -16.2 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.11 | |||||
PB Ratio | 206.25 | |||||
EV-to-EBIT | -7.78 | |||||
EV-to-Forward-EBIT | -7.64 | |||||
EV-to-EBITDA | -9.12 | |||||
EV-to-Revenue | 5.87 | |||||
EV-to-Forward-Revenue | 5.7 | |||||
EV-to-FCF | -7.75 | |||||
Price-to-GF-Value | 1.02 | |||||
Price-to-Median-PS-Value | 0.42 | |||||
Earnings Yield (Greenblatt) % | -12.85 | |||||
FCF Yield % | -23.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pacific Biosciences of California Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 2,934.132 | ||
| EPS (TTM) (MXN) | -7.947 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 26.18 | ||
| 14-Day RSI | 33.91 | ||
| 14-Day ATR (MXN) | 0.00048 | ||
| 20-Day SMA (MXN) | 27.5 | ||
| 12-1 Month Momentum % | 23.76 | ||
| 52-Week Range (MXN) | 22.22 - 31 | ||
| Shares Outstanding (Mil) | 310.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pacific Biosciences of California Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pacific Biosciences of California Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 17:00 | In 39 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 38 days | ||
| Jefferies’ Global Healthcare Conference | 2026-06-04 14:00 | 27.50 (+0.00%) | ||
| General meeting for 2026 | 2026-06-03 09:00 | 27.50 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 27.50 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 27.50 (+0.00%) | ||
| TD Cowen\'s 46th Annual Health Care Conference | 2026-03-02 14:30 | 27.50 (+0.00%) | ||
| Annual report for 2025 | 2026-02-25 | 27.50 (+0.00%) |
Show
Entries
Pacific Biosciences of California Inc Frequently Asked Questions
What is Pacific Biosciences of California Inc(MEX:PACB)'s stock price today?
The current price of MEX:PACB is MXN27.50. The 52 week high of MEX:PACB is MXN31.00 and 52 week low is MXN22.22.
When is next earnings date of Pacific Biosciences of California Inc(MEX:PACB)?
The next earnings date of Pacific Biosciences of California Inc(MEX:PACB) is 2026-08-07 Est..
Does Pacific Biosciences of California Inc(MEX:PACB) pay dividends? If so, how much?
Pacific Biosciences of California Inc(MEX:PACB) does not pay dividend.
Press Release
Articles on Pacific Biosciences of California Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers